The etiology, clinical features and medical treatment of somatotroph adenomas

doi:10.3868/j.issn.2096-0689.2018.01.004

Journal of Translational Neuroscience

2018, Vol. 3

Issue (1) : 23-31 https://doi.org/10.3868/j.issn.2096-0689.2018.01.004

Review

The etiology, clinical features and medical treatment of somatotroph adenomas

Hua Gao¹, Jianhua Li², Yazhuo Zhang^1,3,4*

1.Key Laboratory of Central Nervous System Injury Research, Beijing Neurosurgical Institute, Capital Medical University, Beijing 100050, China
2.Department of Neurosurgery, Binzhou People’s Hospital, Binzhou, Shandong 256610, China
3.Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, China
4.Beijing Neurosurgical Institute, Center of Brain Tumor, Beijing Institute for Brain Disorder, Capital Medical University, Beijing 100050, China

Download: PDF(10912 KB)
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks

Abstract Somatotroph adenomas lead to hypersecretion of growth hormones (GH) and may cause mass effects. Patients with somatotroph adenomas may present with acral and soft tissue enlargement, joint pain, heart and respiratory failure, diabetes mellitus and hypertension, resulting in increased morbidity and mortality. Early diagnosis and treatment are therefore important in prolonging life and improving quality of life. Recent studies depicted the landscape of genetic and epigenetic changes in sporadic somatotroph adenomas. New approaches are being developed for genetic testing, diagnosis and surveillance, which are helpful in early diagnosis, treatment and disease control of somatotroph adenomas. Data suggest that patients with somatotroph adenomas are best treated with multidisciplinary teams composed of neuro-endocrinologists, neurosurgeons, radiation oncologists and other specialists. This mini-review summarizes in a concise way the up-to-date discussion on the etiology, new diagnostic techniques and novel treatments of somatotroph adenomas.

Keywords somatotroph adenomas growth hormone (GH) somatic mutation apparent genetics treatment management

Issue Date: 01 September 2018

Cite this article:

Hua Gao, Jianhua Li, Yazhuo Zhang. The etiology, clinical features and medical treatment of somatotroph adenomas[J]. Journal of Translational Neuroscience,2018, 3(1): 23-31.

URL:

https://academic.hep.com.cn/jtn/EN/10.3868/j.issn.2096-0689.2018.01.004
https://academic.hep.com.cn/jtn/EN/Y2018/V3/I1/23

[1]	Liang Liang, Liwei Wu, Yaowen Hu, Xin Li, Haiqing Dong, Xiaofeng Sun. Effect of improving prehospital hypotension and hypoxemia on the prognosis of patients with traumatic brain injury[J]. Journal of Translational Neuroscience, 2020, 5(2): 34-39.
[2]	Qiaoyan Liu, Yuming Wang, Aimin Zhang. Post-polio syndrome: a literature review[J]. Journal of Translational Neuroscience, 2020, 5(1): 1-7.
[3]	Wenlin Chen, Yang Ge, Yutian Wang. N-methyl-D-aspartate glutamate receptors (NMDARs) in stroke pathogenesis and treatments[J]. Journal of Translational Neuroscience, 2019, 4(4): 1-12.
[4]	Yue Fu, Jianping Jia. Hypertension and Alzheimer’s disease[J]. Journal of Translational Neuroscience, 2017, 2(3): 7-14.
[5]	Rena Li, Xin Ma, Gang Wang, Jian Yang, Chuanyue Wang. Why sex differences in schizophrenia?[J]. Journal of Translational Neuroscience, 2016, 1(1): 37-42.

Viewed

Full text

Abstract

Cited

Shared

Discussed